BioCentury | Oct 14, 2015
Financial News

Audentes raises $65 million in series C

Gene therapy company Audentes Therapeutics Inc. (San Francisco, Calif.) raised $65 million in a series C round co-led by existing investor Sofinnova Ventures and new investor Redmile Group. New investors RA Capital; T. Rowe Price;...
BioCentury | Oct 5, 2015
Company News

Cadiogen, Audentes Therapeutics deal

Audentes acquired fellow rare disease company Cardiogen for an undisclosed amount. Audentes gains AT003 (formerly CASQ2-CPVT ), a preclinical adeno-associated virus (AAV) vector-based therapy that delivers calsequestrin 2 (CASQ2) to cardiomyocytes to treat catecholaminergic polymorphic...
BioCentury | Dec 15, 2014
Finance

Uphill road for Cubist CVRs

When Merck & Co. Inc. (NYSE:MRK) acquires Cubist Pharmaceuticals Inc. (NASDAQ:CBST), the pharma will take over the contingent value rights the infectious disease company owes the former shareholders of Optimer Pharmaceuticals Inc. and Trius Therapeutics...
BioCentury | Mar 31, 2014
Financial News

Generex completes private placement of units

Generex Biotechnology Corp. (OTCBB:GNBT), Toronto, Ontario Business: Drug delivery Date completed: 3/27/14 Type: Private placement of units Raised: $2.1 million Units: 2,075 Price: $1,000 (unit) Shares outstanding prior: 730.5 million Investors: Institutional investors Note: Each...
BioCentury | Jun 24, 2013
Financial News

Generex completes private placement of units

Generex Biotechnology Corp. (OTCBB:GNBT), Toronto, Ontario Business: Drug delivery Date completed: 6/17/13 Type: Private placement of units Raised: $1.2 million Units: 1,225 Price: $1,000 (unit) Shares outstanding prior: 531.5 million Investors: Institutional investors Note: Each...
BioCentury | Dec 17, 2012
Financial News

Generex completes private placement of convertible preferred units

Generex Biotechnology Corp. (OTCBB:GNBT), Toronto, Ontario Business: Drug delivery Date completed: 12/11/12 Type: Private placement of convertible preferred units Raised: $750,000 Shares: 750 Price: $1,000 (unit) Placement agent: Seahawk Capital Partners Shares outstanding prior: 372.1...
BioCentury | Nov 28, 2012
Company News

Mymetics names Kempers president and CEO

Vaccine company Mymetics Corp. (OTCBB:MYMX) appointed CFO and COO Ronald Kempers as president and CEO. He replaces President and CEO Grant Pickering and Chairman Christopher Henney. Pickering and Henney were hired in March in connection...
BioCentury | Feb 26, 2007
Company News

Pluristem Life Systems Inc., Stem Cell Innovations deal

SCLL received rights to market PLRS's PLX-1 and 3-D PluriX bioreactor in Asia, excluding Japan. PLX-1 is an adjuvant cell therapy based on placenta-expanded mesenchymal cells. PLX-1 is currently in preclinical studies as an alternative...
BioCentury | May 24, 2001
Top Story

Mostly positive Natrecor review

The FDA on Thursday released its review of Scios' Natrecor nesiritide recombinant b-type natriuretic peptide (BNP) for acute congestive heart failure, which is to be reviewed on Friday by the Cardiovascular Renal Drugs Advisory Committee....
Items per page:
1 - 9 of 9